Cullen/Frost Bankers, Inc. Vaxcyte, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.21 Billion
- Q4 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 39 shares of PCVX stock, worth $3,331. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39
Previous 34
14.71%
Holding current value
$3,331
Previous $3,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PCVX
# of Institutions
357Shares Held
129MCall Options Held
760KPut Options Held
430K-
Vanguard Group Inc Valley Forge, PA12MShares$1.02 Billion0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$933 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$849 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$742 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$418 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.07B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...